Biotechnology

Nucana

Nucana released FY2025 9 Months Earnings on November 13 (EST) with actual revenue of USD 0 and EPS of USD -137.493

Nucana released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1021 (forecast USD -2.6)

NuCana plc Secures Substance Composition Patent for NUC-7738 Cancer Drug

NuCana Reports Positive Results for NUC-7738 in Combination with PD-1 Inhibitors

Nucana released FY2025 Q2 earnings on August 20 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -31.9451 (forecast USD -2.6)

Nucana released FY2025 Semi-Annual earnings on August 20, 2025, EST with actual revenue USD 0 and EPS USD -66.1879

NuCana PLC Plans to Adjust ADS Ratio

NuCana PLC May Issue Up to $100 Million ADS

NuCana Terminates $100 Million Stock Sale Agreement with Jefferies

NuCana PLC CEO Steps Down for Health Reasons, Appoints New Interim CFO

Expansion of NUC-7738 and Pembrolizumab Combination Therapy for Melanoma

Nucana released FY2025 Q1 earnings on June 2 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -105.4458 (forecast USD -2.6)

Nucana released FY2024 annual earnings on March 20 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -8.1898 USD (forecast -12.55 USD)

Nucana released FY2024 Q4 earnings on March 20 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -62.73 (forecast USD -440)

Nucana released FY2024 9 Months earnings on November 25 (EST), actual revenue USD 0, actual EPS USD -2.085 K

Nucana released FY2024 Q3 earnings on November 25 (EST), actual revenue 0 (forecast 0), actual EPS -2.4969 (forecast -3.56)

Nucana released FY2024 Semi-Annual earnings on August 15 (EST), actual revenue USD 0, actual EPS USD -1.585 K

Nucana released FY2024 Q2 earnings on August 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -780.3083 (forecast USD -722)

Nucana released FY2024 Q1 earnings on May 16 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -805.29 (forecast USD -698.75)

Nucana released FY2023 Q4 earnings on March 20 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -892.43 (forecast USD -640)

A SPAC III Acquisition

PicoCELA

Davis Commodities

ECD Automotive Design

Universe Pharmaceuticals

Functional Brands

Starfighters Space

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Northann

Paranovus ENT Tech

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap